KWM
TRVI icon

Kingsview Wealth Management’s Trevi Therapeutics TRVI Stock Holding History

Kingsview Wealth Management’s Portfolio TRVI Stock Details TRVI Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$296K Buy
15,895
+125
+0.8% +$1.82K ﹤0.01% 1202
2026
Q1 		$188K Buy
15,770
+5,132
+48% +$57.5K ﹤0.01% 1268
2025
Q4 		$133K Buy
+10,638
New +$123K ﹤0.01% 1204

Other funds holding TRVI

NMC
NEA Management Company Timonium, Maryland $1.59B AUM 234.06% 1-Year Est. Return
Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
FLSM
Frazier Life Sciences Management Palo Alto, California $4.59B AUM 237.58% 1-Year Est. Return
Wellington Management Group
Wellington Management Group Boston, Massachusetts $580B AUM 38.23% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
VC
Vivo Capital Palo Alto, California $1.1B AUM 799.93% 1-Year Est. Return
WP
Woodline Partners San Francisco, California $32.4B AUM 58.5% 1-Year Est. Return
VPC
Vestal Point Capital New York $4.28B AUM 239% 1-Year Est. Return
MB
MPM BioImpact Boston, Massachusetts $1.64B AUM 245.64% 1-Year Est. Return

Kingsview Wealth Management's TRVI Position: Q2 2026 in Review

Kingsview Wealth Management increased its Trevi Therapeutics (TRVI) stake by 0.79% in Q2 2026, buying an estimated $1.82K and bringing the position to 15,895 shares worth $296K. The position accounts for ﹤0.01% of the portfolio, ranked #1202.

Kingsview Wealth Management first reported a position in TRVI in Q4 2025 and has held it in 3 quarters since. 219 funds tracked by Wall St. Rank hold TRVI as of Q2 2026.

  • Kingsview Wealth Management held 15,895 shares of Trevi Therapeutics worth $296K as of Q2 2026.
  • Kingsview Wealth Management bought 125 Trevi Therapeutics shares in Q2 2026, an estimated $1.82K.
  • Trevi Therapeutics made up ﹤0.01% of Kingsview Wealth Management's portfolio in Q2 2026, its #1202 holding.
  • Kingsview Wealth Management first reported a position in Trevi Therapeutics in Q4 2025 and has held it in 3 quarters since.
  • 219 funds tracked by Wall St. Rank held Trevi Therapeutics as of Q2 2026.

Based on Kingsview Wealth Management's 13F filing for Q2 2026, filed 19 Aug 2026.